Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer

By D. Danila, G. Heller, G. Gignac, Rita Gonzalez-Espinoza, A. Anand, E. Tanaka, Hans Lilja, Lawrence H. Schwartz, S. Larson, M. Fleisher and 1 more. Clinical Cancer Research, 2007

638 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/ec83aae02f02c10d1729daa8faab20f251198c2c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. K. Pantel
2. Ruud H. Brakenhoff
3. B. Brandt
4. R. DePinho
5. C. Alix‐Panabières

In Oncology

1. K. Pantel
2. Ruud H. Brakenhoff
3. B. Brandt
4. R. DePinho
5. C. Alix‐Panabières
6. Jing Yang
7. J. Tsai
8. J. Massagué

In Pulmonary and Respiratory Medicine

1. K. Pantel

Citations in the corpus

• Circulating tumor cells: approaches to isolation and characterization (2011, background): “As with breast cancer, a correlation between pretreatment CTC numbers and clinical prognosis has been reported for patients with colorectal (Cohen et al., 2006) and prostate cancers (Danila et al., 2007; de Bono et al., 2008; Okegawa et al., 2009).”
• Detection, clinical relevance and specific biological properties of disseminating tumour cells (2008, background): “, and has the potential to evaluate CTCs in pharmacodynamic studies testing new targeted therapie”
• Genetics and biology of prostate cancer (2018, background): “Baseline CTC count (Danila et al. 2007, 2011; de Bono et al. 2008; Scher et al. 2009; Goldkorn et al. 2014; Scher et al. 2015) and changes in posttreatment CTC count (Olmos et al. 2009; Scher et al. 2009; Goldkorn et al. 2014) were found to be prognostic factors for overall survival in prostate…”
• Exosomal miR-1290 and miR-375 as Prognostic Markers in Castration-resistant Prostate Cancer (2014, neutral): “5 ml blood [4,5].”